Nov. 11, 2000 Trade Star Medicine Technology Development Co., Ltd was founded.

2003 more than a dozen products of TRADE STAR had covered military hospitals of national wide, cefuroxime led the way. At the same time, we established sales network in Hebei and Tianjin.

At the beginning of 2003, Thymopathy injection sold by TRADE STAR prominently contributed to control the spread of SARS broke out in Beijing.

2004 Thymopathy injection sold by TRADE STAR covered majority domestic markets achieving outstanding performance, and sales volume was more than 100 million.

October, 2004 Mr. Li Chao, the board chairman of TRADE STAR, is appointed as the director of Society of Infectious Diseases, CMA

August, 2005 “Thymopentin for Injection”of TRADE STAR got the approval of government and achieved the sales of millions.

April, 2006 “Monosialotetrahexosylganglioside Sodium” developed by TRADE STAR got the approval of government.

May, 2006 “Cefdinir” developed by TRADE STAR was launched in market.

June, 2006 TRADE STAR was titled “Beijing High Tech Enterprise”

July, 2007 Mr. Li Chao, the board chairman of TRADE STAR, is appointed as the director of Beijing Pharmacist Association

Feb.4, 2009 Beijing Trade Star Medicine Biological Technology Co., Ltd. was founded.

May 1, 2009 Trade Star Investment Holding Group (S) Pte., Ltd. was founded.

May 21, 2009 Trade Star (Beijing) International Investment Co., Ltd. was founded.

June 30,2009 Trade Star (Beijing) International Investment Co., Ltd and Trade Star (Beijing) Medicine Biological Technology were respectively appointed as the high-tech enterprises in Zhongguancun and passed examination in 2011.

Aug, 2009 TRADE STAR moved into Advanced Business Park Building, locating in the west north of business center in Beijing.

2009, the sales volume of Monosialotetrahexosylganglioside Sodium sold by TRADE STAR ranked second in national wide.

2010, the market share of classⅡhospitals and revenue of Cefdinir Dispersible Tablet distributed exclusively by TRADE STAR respectively ranked first in national wide.

Feb 5,2010 Trade Star (Hongkong) International Medicine Co., Ltd was founded.

Sep , 2010 Vancomycin Hydrochloride Injection produced by Zhengjiang Haizheng Pharmaceutical company was distributed exclusively by Trade Star.

Jan 2012, Mr. Li Chao, the board chairman of TRADE STAR, is appointed as Director of Chinese medicine enterprise management association.

Feb 2011, Cefazedone Sodium for injection produced by SHIN POONG PHARMACEUTICAL CO., Ltd was imported exclusively by TRADE STAR and sold in national wide.

Mar 2012, Chengchuangkangyun (Beijing) Medicine Technology Co., Ltd was acquired by TRADE STAR, representing the R&D Department of TRADE STAR was formally founded.

May 2013, Jinyanglikang (Beijing) Medicine Co., Ltd was successfully acquired by TRADE STAR , representing the whole industrial chain of pharmaceutical commerce had been accomplished.

July 31, 2013 It was formally established that Trade Star will build the Group’s own training and holiday center in the beautiful Ji county in Tianjin and already finished the land acquisition of 20 acres.

March, 2014 The Beijing Zhongzhi Medical Technology Co., Ltd. that locates in the petrochemical new material science and technology industry base in Yanshan, Beijing was incorporated which means Trade Star Holding Group’s industrial chain was fully opened up.

March 16, 2014 Trade Star’s engineering project in petrochemical new material science and technology industry base in Yanshan, Beijing was officially started. The first phase of this project would be finished in June, 2014 as the modernized logistics center project for the GSP authentication of Trade Star’s affiliated medical company.

June 6, 2014 Trade Star signed the Pharmaceutical Factory Capital Increase and Share Expansion Cooperation Agreement with the Yunnan No.1 Fuel Factory. Then Trade Star went through with the merger of Yunnan Yongan Pharmaceutical Co. Ltd. which means a solid step towards the medical industry field.

June 27, 2014 The company-directed Ademetionine 1,4-butanedisulfonate for Injection was approved by the China’s State Food and Drug Administration (SFDA).

July 24, 2014 The new product releasing conference of ‘Ademetionine 1,4-butanedisulfonate for Injection’ was held in Kunming, Yunnan which means its access to market for selling.

August 26, 2014 Beijing Jinyang Likang Medicine Co., Ltd. pass the newly revised Good Supply Practice (GSP) authentication and gained the new GSP certification.

July 16, 2015Yunnan Yongan Pharmaceutical Co., Ltd., the subsidiary company of TradeStar ( Beijing ) Pharmaceutical Holding Group Co., Ltd. obtain the new GMP certificate.

June 12, 2016, TradeStar acquired Xizang Jianlian Medicine Co., Ltd. with 100% equity which means TS made a new breakthrough in the medicine commercial field.

July 4, 2016, TradeStar and GSK signed the agreement on purchasing 100% equity of Nanjing Meirui Pharmaceutical Co., Ltd. which means a further improvement of TradeStar in medical industry.